The REnal Patients COVID-19 VACcination Immune Response (RECOVAC IR) Study

NCT ID: NCT04741386

Last Updated: 2022-04-04

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 854 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-02-17
• Study Completion Date: 2022-02-25

Brief Summary

Rationale: COVID-19 is associated with severely increased morbidity and mortality in patients with severely impaired kidney function, on dialysis or alive with a kidney transplant. Therefore, effective SARS-CoV-2 vaccination would be of great clinical importance in these patients. However, SARS-CoV-2 vaccination studies have excluded patients with chronic kidney disease (CKD) so-far.

Objective: To assess the efficacy and safety of SARS-CoV-2 vaccination in patients with CKD stages 4/5, on dialysis or alive with a kidney transplant as compared to controls.

Study design: prospective, controlled multicenter study Study population: 175 patients with CKD stages 4/5 (eGFR < 30 ml/min/1.73m2), 175 on dialysis , 300 alive with a kidney transplant and 200 controls (partners or sibblings of patients) Intervention: SARS-CoV-2 vaccination according to standard of care. Blood will be drawn at 4 different time points (baseline and at day 28, month 6 and in a subset 28 days after a third vaccination).

Main study parameters/endpoints: The primary endpoint is the antibody based immune response on day 28 after the second vaccination. Participants will be classified as responders or non-responders based on a spike (S)1 specific antibody levels of >=10 or <10 BAU/mL. The percentage of responders of each patient cohort will be compared with the percentage responders in the control group. Safety is a secondary endpoint which will be reported in terms of percentage of solicited local and systemic adverse events (AEs)graded according to severity. Other secondary endpoints include longevity of the immune response at 6 months, antibody respons 28 days after a third vaccination and levels of SARS-CoV-2 specific T and B cell responses.

Detailed Description

OBJECTIVES

Primary objective:

To assess the antibody response after SARS-CoV-2 vaccination in patients with CKD stages 4/5, on dialysis or alive with a kidney transplant as compared to controls.

Secondary Objectives:

To assess in these groups of subjects after SARS-CoV 2 vaccination:

• durability of the antibody response
• the SARS-CoV-2-specific T and B cell response
• adverse events
• antibody response after third vaccination in patients on dialysis and kidney transplant recipients

Exploratory Objectives:

To assess in these groups of subjects after SARS-CoV 2 vaccination:

• the association between baseline (immune) parameters and the immune response to SARS-CoV-2 vaccination
• the neutralizing capacity of anti-COVID-19 antibodies
• the incidence of SARS-CoV-2 infection and outcome of COVID-19 disease during 6 months after SARS-CoV-2 vaccination and in a subset 28 days after third vaccination

STUDY DESIGN

This is a prospective, controlled multicenter cohort study to evaluate the efficacy and safety after SARS-CoV-2 vaccination in patients with CKD4/5, dialysis patients and kidney transplant recipients as compared to controls. Therefore, 4 cohorts will be included in this study.

• Cohort A: Patients with CKD stages 4 and 5 (eGFR <30 ml/min*1.73m2) (n = 175)
• Cohort B: Patients on hemodialysis and peritoneal dialysis (n = 175)
• Cohort C: Kidney Transplant Recipients (n= 300)
• Cohort D: Controls (n = 200)

Assessment of immune response:

Blood samples will be collected at baseline (i.e. prior to first vaccination) and 28 days, and 6 months after the second vaccination and in a subset 28 days after the third vaccination.

Evaluation other parameters:

To evaluate hematology parameters, liver and kidney function, additional blood samples will be collected at baseline, and 28 days and 6 months after the second vaccination.

Information on clinical course, incidence of SARS-CoV-2 infection, outcome of COVID-19 will be collected up to 6 months after second and in a subset 28 days after third vaccination for descriptive purposes.

METHODS

Main study parameter/endpoint:

The primary endpoint is the antibody based immune response to vaccination against COVID-19 on day 28 after the second vaccination as compared to controls.

Secondary study parameters/endpoints:

1. Duration and in-depth assessment of immune response through:

• Measurement of SARS-CoV2 specific antibodies at 6 months after vaccination to test the durability of response
• Assessment of SARS-CoV2 specific T and B cell response, 28 days, and 6 months after the second vaccination using a high throughput Interferon ɣ, IL-21 SARSCoV-2 specific T cell ELISPOT and SARS-CoV2 specific B cell memory ELISPOT.

2. Safety assessment through:

• Incidence and severity of solicited AEs during 7 days after each vaccination

3. Antibody based immune response after third vaccination:

• Measurement of SARS-CoV-2 specific antibodies at 28 days after third vaccination in patients on dialysis and kidney transplantation recipients.

Exploratory study parameters:

• Baseline (immune) parameters associated with vaccination response
• Neutralizing capacity of antibodies to test functionality
• In-depth flow-cytometric analyses for functional and phenotypical characterization of SARS-CoV-2 specific T cell responses will be performed followed by assessment of proliferative capacity, cytokine production and phenotypical markers in a subset of patients.
• Information on incidence of SARS-CoV-2 infection and outcome of COVID-19 disease during 6 months after second vaccination and in a subset 28 days after third vaccination will be collected.
• In a substudy in Radboudumc nasal strips will be collected and mucosal antibody response to COVID-19 analysed

Conditions

Covid19; Chronic Kidney Diseases

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Cohort A

Patients with CKD stages 4 and 5

SARS-CoV-2 vaccination

Intervention Type: BIOLOGICAL

All participants will receive two vaccinations against COVID-19 according to the manufacturer's instructions.

Cohort B

Patients on hemodialysis and peritoneal dialysis

SARS-CoV-2 vaccination

Intervention Type: BIOLOGICAL

All participants will receive two vaccinations against COVID-19 according to the manufacturer's instructions.

Cohort C

Kidney Transplant Recipients

SARS-CoV-2 vaccination

Intervention Type: BIOLOGICAL

All participants will receive two vaccinations against COVID-19 according to the manufacturer's instructions.

Cohort D

Controls

SARS-CoV-2 vaccination

Intervention Type: BIOLOGICAL

All participants will receive two vaccinations against COVID-19 according to the manufacturer's instructions.

Interventions

SARS-CoV-2 vaccination

All participants will receive two vaccinations against COVID-19 according to the manufacturer's instructions.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. All patients should be eligible for COVID-19 vaccination as described by the instructions of the manufacturer.

2. Age of 18 years or older

3. Capable of understanding the purpose and risks of the study, fully informed and given written informed consent

4. Either

• CKD4/5, with an eGFR <30 ml/min*1.73m2 by CKD-EPI
• Hemodialysis, or peritoneal dialysis
• KT recipient at least 6 weeks after transplantation
• Partner, sibling or family member of participating patient

Exclusion Criteria

• History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of the study intervention(s)
• Multi-organ transplant recipients
• Previous or active COVID-19 disease
• Pregnancy or breastfeeding
• Active (haematological) malignancy
• Inherited immune deficiency
• Infection with Human Immunodeficiency Virus (HIV)
• Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.

Additional exclusion criterion for patients with CKD stages 4/5, on dialysis and controls:

• Individuals who receive maintenance treatment with immunosuppressive therapy in the 6 months before inclusion, including cytotoxic agents or systemic corticosteroids.

Additional exclusion criterion for controls:

• severely impaired kidney function, with an eGFR < 45 ml/min*1.73m2 by CKD-EPI

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Erasmus Medical Center

OTHER

Sponsor Role: collaborator

Radboud University Medical Center

OTHER

Sponsor Role: collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

Sponsor Role: collaborator

University Medical Center Groningen

OTHER

Sponsor Role: lead

Responsible Party

J.S.F. Sanders

MD PhD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jan-Stephan F Sanders, MD PhD

Role: STUDY_DIRECTOR

University Medical Center Groningen

Ron T Gansevoort, MD PhD

Role: PRINCIPAL_INVESTIGATOR

University Medical Center Groningen

Luuk B Hilbrands, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Radboud University Medical Center

Marlies EJ Reinders, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Erasmus Medical Center

Frederike J Bemelman, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Locations

Radboud university medical center

Nijmegen, Gelderland, Netherlands

Amsterdam University Medical Center

Amsterdam, North Holland, Netherlands

Erasmus Medical Center

Rotterdam, South Holland, Netherlands

University Medical Center Groningen

Groningen, , Netherlands

Countries

Netherlands

References

Ahn C, Amer H, Anglicheau D, Ascher NL, Baan CC, Battsetset G, Bat-Ireedui B, Berney T, Betjes MGH, Bichu S, Birn H, Brennan D, Bromberg J, Caillard S, Cannon RM, Cantarovich M, Chan A, Chen ZS, Chapman JR, Cole EH, Cross N, Durand F, Egawa H, Emond JC, Farrero M, Friend PJ, Geissler EK, Ha J, Haberal MA, Henderson ML, Hesselink DA, Humar A, Jassem W, Jeong JC, Kaplan B, Kee T, Kim SJ, Kumar D, Legendre CM, Man K, Moulin B, Muller E, Munkhbat R, Od-Erdene L, Perrin P, Rela M, Tanabe K, Tedesco Silva H, Tinckam KT, Tullius SG, Wong G. Global Transplantation COVID Report March 2020. Transplantation. 2020 Oct;104(10):1974-1983. doi: 10.1097/TP.0000000000003258. No abstract available.

Reference Type: BACKGROUND

PMID: 32243281 (View on PubMed)

Gansevoort RT, Hilbrands LB. CKD is a key risk factor for COVID-19 mortality. Nat Rev Nephrol. 2020 Dec;16(12):705-706. doi: 10.1038/s41581-020-00349-4.

Reference Type: BACKGROUND

PMID: 32848205 (View on PubMed)

Gezondheidsraad. Strategieën voor COVID-19-vaccinatie. Den Haag: Gezondheidsraad, 2020; publicatienr. 2020/23

Reference Type: BACKGROUND

Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Hemmelder MH, Jager KJ, Kieneker LM, Noordzij M, Pena MJ, Vries H, Arroyo D, Covic A, Crespo M, Goffin E, Islam M, Massy ZA, Montero N, Oliveira JP, Roca Munoz A, Sanchez JE, Sridharan S, Winzeler R, Gansevoort RT; ERACODA Collaborators. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant. 2020 Nov 1;35(11):1973-1983. doi: 10.1093/ndt/gfaa261.

Reference Type: BACKGROUND

PMID: 33151337 (View on PubMed)

Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021 Feb;21(2):e26-e35. doi: 10.1016/S1473-3099(20)30773-8. Epub 2020 Oct 27.

Reference Type: BACKGROUND

PMID: 33125914 (View on PubMed)

Katerinis I, Hadaya K, Duquesnoy R, Ferrari-Lacraz S, Meier S, van Delden C, Martin PY, Siegrist CA, Villard J. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant. 2011 Aug;11(8):1727-33. doi: 10.1111/j.1600-6143.2011.03604.x. Epub 2011 Jun 14.

Reference Type: BACKGROUND

PMID: 21672157 (View on PubMed)

Kotton CN. Immunization after kidney transplantation-what is necessary and what is safe? Nat Rev Nephrol. 2014 Oct;10(10):555-62. doi: 10.1038/nrneph.2014.122. Epub 2014 Jul 29.

Reference Type: BACKGROUND

PMID: 25072119 (View on PubMed)

Mahase E. Covid-19: Vaccine candidate may be more than 90% effective, interim results indicate. BMJ. 2020 Nov 9;371:m4347. doi: 10.1136/bmj.m4347. No abstract available.

Reference Type: BACKGROUND

PMID: 33168562 (View on PubMed)

Reddy S, Chitturi C, Yee J. Vaccination in Chronic Kidney Disease. Adv Chronic Kidney Dis. 2019 Jan;26(1):72-78. doi: 10.1053/j.ackd.2018.10.002.

Reference Type: BACKGROUND

PMID: 30876620 (View on PubMed)

van Besouw NM, Yan L, de Kuiper R, Klepper M, Reijerkerk D, Dieterich M, Roelen DL, Claas FHJ, Clahsen-van Groningen MC, Hesselink DA, Baan CC. The Number of Donor-Specific IL-21 Producing Cells Before and After Transplantation Predicts Kidney Graft Rejection. Front Immunol. 2019 Apr 9;10:748. doi: 10.3389/fimmu.2019.00748. eCollection 2019.

Reference Type: BACKGROUND

PMID: 31024571 (View on PubMed)

Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L, Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug;584(7821):430-436. doi: 10.1038/s41586-020-2521-4. Epub 2020 Jul 8.

Reference Type: BACKGROUND

PMID: 32640463 (View on PubMed)

Vervoort JPM, Konijn WS, Jansen DEMC, Boersma C, de Zeeuw J, Ho-Dac-Pannekeet MM, Gansevoort RT, Messchendorp AL, Sanders JSF, de Wildt-Liesveld R. Patient engagement as a collaborative process in a large Dutch COVID-19 vaccination study (RECOVAC) - insight into the contribution of patient engagement and learnings for the future. Res Involv Engagem. 2024 Sep 13;10(1):96. doi: 10.1186/s40900-024-00622-x.

Reference Type: DERIVED

PMID: 39272117 (View on PubMed)

Sanders JF, Messchendorp AL, de Vries RD, Baan CC, van Baarle D, van Binnendijk R, Diavatopoulos DA, Geers D, Schmitz KS, GeurtsvanKessel CH, den Hartog G, Kho MML, Koopmans MPG, van der Molen RG, Remmerswaal EBM, Rots N, Gansevoort RT, Bemelman FJ, Hilbrands LB, Reinders MEJ; VACcination Immune Response Study (RECOVAC) Collaborators. Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Clin Infect Dis. 2023 Feb 8;76(3):e188-e199. doi: 10.1093/cid/ciac557.

Reference Type: DERIVED

PMID: 35796536 (View on PubMed)

Sanders JF, Bemelman FJ, Messchendorp AL, Baan CC, van Baarle D, van Binnendijk R, Diavatopoulos DA, Frolke SC, Geers D, GeurtsvanKessel CH, den Hartog G, van der Heiden M, Imhof C, Kho MML, Koopmans MPG, Malahe SRK, Mattheussens WB, van der Molen R, van Mourik D, Remmerswaal EBM, Rots N, Vart P, de Vries RD, Gansevoort RT, Hilbrands LB, Reinders MEJ; RECOVAC Collaborators. The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Transplantation. 2022 Apr 1;106(4):821-834. doi: 10.1097/TP.0000000000003983.

Reference Type: DERIVED

PMID: 34753894 (View on PubMed)

Other Identifiers

NL76215.042.20

Identifier Type: -

Identifier Source: org_study_id